Krystal Biotech (KRYS) received a STRONG BUY rating due to its solid financial position, high profit margins, and successful commercial launch of Vyjuvek in Europe and Japan. The company's expansion into additional European markets like Italy, Spain, and the UK is expected to further increase revenue. KRYS also has a diverse pipeline beyond Vyjuvek, targeting respiratory, eye, cancer, and aesthetic treatments using its proprietary HSV-1 platform, which reduces dependency on a single product. Despite risks from high valuation and biotech competition, the broad pipeline and careful capital management support long-term growth potential.
Guangzhou's Nansha District is rapidly advancing as a global cross-border trade hub with its state-of-the-art automated container terminal and integrated multimodal transport system. In 2025, Nansha Port handled over 22.6 million TEUs and operates 18...
Nord Precious Metals Mining Inc., focused on high-grade silver mining in Northern Ontario, announced that CEO Frank J. Basa will present live at the OTCQB Virtual Investor Conference on August 5, 2026. The event allows investors to engage directly wi...
YieldMax ETFs declared weekly distributions for their Group 1 ETFs, effective August 6, 2026. Distribution rates vary widely across ETFs, reflecting different investment strategies and associated risks, including semiconductor, AI, crypto, metals, an...
The global military drone market is expected to grow from $16.5 billion in 2025 to $42.8 billion by 2035, at a CAGR of 10%. Growth is fueled by AI-powered autonomous systems, defense modernization, and rising demand for surveillance, electronic warfa...
Man Group PLC has disclosed a 1.66% interest in Senior Plc's ordinary shares, totaling 6,962,764 shares, held through cash-settled derivatives as of August 3, 2026. The stake was increased by 104,804 shares via an equity swap transaction priced at ap...
